ANPAC BIO-MED SP.ADS/20 A
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developi… Read more
ANPAC BIO-MED SP.ADS/20 A (0UC0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ANPAC BIO-MED SP.ADS/20 A (0UC0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ANPAC BIO-MED SP.ADS/20 A - Net Assets Trend (None–None)
This chart illustrates how ANPAC BIO-MED SP.ADS/20 A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ANPAC BIO-MED SP.ADS/20 A (None–None)
The table below shows the annual net assets of ANPAC BIO-MED SP.ADS/20 A from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ANPAC BIO-MED SP.ADS/20 A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ANPAC BIO-MED SP.ADS/20 A Competitors by Market Cap
The table below lists competitors of ANPAC BIO-MED SP.ADS/20 A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinew Pharma Inc.
TWO:6634
|
$45.36 Million |
|
Afya Limited
SA:A2FY34
|
$45.37 Million |
|
Khon Kaen Sugar Industry PCL
BK:KSL
|
$45.37 Million |
|
TITANIUM TRANSPORT.GROUP
F:I9V
|
$45.38 Million |
|
ICD Co. Ltd
KQ:040910
|
$45.30 Million |
|
Horizon Space Acquisition II Corp. Units
NASDAQ:HSPTU
|
$45.29 Million |
|
WIELTON S.A. ZY-20
F:2W1
|
$45.28 Million |
|
APS Holdings Corporation
KQ:054620
|
$45.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANPAC BIO-MED SP.ADS/20 A's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ANPAC BIO-MED SP.ADS/20 A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ANPAC BIO-MED SP.ADS/20 A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ANPAC BIO-MED SP.ADS/20 A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANPAC BIO-MED SP.ADS/20 A (0UC0) | €- | N/A | N/A | $45.32 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |